Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Chordoma × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Transitional Cell 25 Urinary Bladder Neoplasms 23 Neoplasms 20 Carcinoma, Merkel Cell 20 Carcinoma, Renal Cell 18 Neoplasm Metastasis 17 Colorectal Neoplasms 15 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 12 Ovarian Neoplasms 12 Triple Negative Breast Neoplasms 8 Head and Neck Neoplasms 8 Pancreatic Neoplasms 7 Stomach Neoplasms 6 Melanoma 6 Recurrence 5 Prostatic Neoplasms 5 Carcinoma, Hepatocellular 5 Ureteral Neoplasms 4 Small Cell Lung Carcinoma 4 Neuroendocrine Tumors 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Turcot syndrome 3 Skin Neoplasms 3 Sarcoma 3 Lymphoma 3

Interventions

Nivolumab 6 Imatinib Mesylate 4 Ipilimumab 3 palbociclib 2 Specimen Handling 2 Radiosurgery 2 Protons 2 Proton Therapy 2 Pemetrexed 2 Magnetic Resonance Spectroscopy 2 Cyclophosphamide 2 Cetuximab 2 tazemetostat 1 spartalizumab 1 relatlimab 1 pembrolizumab 1 camrelizumab 1 avelumab 1 atezolizumab 1 apatinib 1 Zoledronic Acid 1 X-Rays 1 Tiragolumab 1 Thiotepa 1 Surveys and Questionnaires 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy 1 Radiation 1 Photochemotherapy 1 Phantoms, Imaging 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03647423 2025-02-21

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

ImmunityBio, Inc.

Phase 1/2 Withdrawn

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡